Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.54M | 34.80M | 31.68M | 31.10M | 30.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.54M | 34.80M | 31.68M | 31.10M | 30.62M |
| Cost of Revenue | 9.77M | 9.37M | 8.15M | 7.24M | 7.25M |
| Gross Profit | 24.76M | 25.43M | 23.53M | 23.86M | 23.37M |
| SG&A Expenses | 34.24M | 35.10M | 36.73M | 37.99M | 38.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.35M | 51.38M | 54.46M | 56.71M | 59.54M |
| Operating Income | -15.81M | -16.58M | -22.78M | -25.61M | -28.92M |
| Income Before Tax | -17.53M | -22.14M | -19.95M | -26.81M | -28.82M |
| Income Tax Expenses | -1.69M | -1.69M | -813.70K | -813.70K | -813.70K |
| Earnings from Continuing Operations | -15.84 | -20.45 | -19.14 | -26.00 | -28.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.84M | -20.45M | -19.14M | -26.00M | -28.01M |
| EBIT | -15.81M | -16.58M | -22.78M | -25.61M | -28.92M |
| EBITDA | -14.27M | -15.01M | -21.21M | -24.02M | -27.32M |
| EPS Basic | -0.29 | -0.38 | -0.37 | -0.54 | -0.60 |
| Normalized Basic EPS | -0.20 | -0.25 | -0.25 | -0.35 | -0.39 |
| EPS Diluted | -0.29 | -0.38 | -0.37 | -0.54 | -0.60 |
| Normalized Diluted EPS | -0.20 | -0.25 | -0.25 | -0.35 | -0.39 |
| Average Basic Shares Outstanding | 224.21M | 217.91M | 209.75M | 199.67M | 189.38M |
| Average Diluted Shares Outstanding | 224.21M | 217.91M | 209.75M | 199.67M | 189.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |